Vascular Disruptive Agents for the Treatment of Cancer

ISBN 10: 1441966080 / ISBN 13: 9781441966087
Used / Quantity Available: 0
Available From More Booksellers
View all  copies of this book

About the Book

We're sorry; this specific copy is no longer available. AbeBooks has millions of books. We've listed similar copies below.

Description:

Vascular Disruptive Agents for the Treatment of Cancer. Bookseller Inventory #

About this title:

Book ratings provided by Goodreads:
0 avg rating
(0 ratings)

Synopsis: Angiogenesis (formation of new vessels from pre-existing ones) is a crucial early event in the process of tumor development. New vessels supply the tumor with nutrients that are needed for further local growth and enable distant metastases (Folkman 1995). Judah Folkman (1971) highlighted the potential therapeutic imp- cations of tumor angiogenesis. He hypothesized that if tumor angiogenesis is inhibited, then tumor growth and metastasis will be impaired greatly or even impossible. The subsequent quest for endogenous and exogenous inhibitors of angiogenesis has yielded a variety of promising therapeutic agents that block one or more angiogenic pathways, a few of which have been approved by the FDA (e. g. , bevacizumab, sorafenib, sunitinib) for use as single agents or in combination with chemotherapy in specific populations of cancer patients (Sessa et al. 2008). There has also been a dramatic expansion in the exploration of novel anti-angiogenic agents pre-clinically and in clinical trials (Ferrara 2002). Some of the most promising data comes from the development of agents that inhibit one of the key growth factors involved in tumor angiogenesis – vascular endothelial growth factor (VEGF) (Ferrara et al. 2003). Bevacizumab is a monoclonal antibody against VEGF that was the first an- angiogenic agent that improved significantly the overall survival of patients with colorectal and non-squamous non-small cell lung cancer (Ferrara et al. 2005). Various agents that target tumor angiogenesis are currently under investigation in different cancer types in many clinical trials (Ferrara and Kerbel 2005).

From the Back Cover: Tumour survival and growth is critically dependent on an independent blood supply. As such tumour vasculature presents an ideal target for cancer therapy that is widely applicable, accessible and genetically stable rendering it less prone to resistance. Two approaches have been explored for cancer therapy; firstly the prevention of new vessel formation with inhibitors of angiogenesis, and secondly the destruction of existing tumour blood vessels with so called vascular disruptive agents (VDAs). While the first approach appears to delay tumour progression, the second has the potential to cause massive cell death and tumour regression. It is the second approach of vascular targeting that is the focus of this book. Since the tubulin binding agent combretastatin, derived from the bark of the African bush willow, was discovered by George R Pettit to have antimitotic properties over twenty years ago, the field of vascular targeting has expanded steadily. Coincident with the preclinical and clinical development of these agents, there have been advances in our understanding of their mechanism of action and in the technology required to assess their effects. This book aims to provide a comprehensive account of the current state of the art. Preclinical target identification and validation are discussed and the optimum pre-clinical animal models described. The imaging modalities that can be used to assess the efficacy of these agents are examined and a comprehensive review of the clinical development of key drugs is provided. Finally, the recent research exploring rational combinations of VDAs with other agents is reviewed and the potential place of VDAs in the future of cancer therapy is critically appraised.

"About this title" may belong to another edition of this title.

Bibliographic Details

Title: Vascular Disruptive Agents for the Treatment...
Book Condition: Good

Top Search Results from the AbeBooks Marketplace

1.

Editor-Tim Meyer
Published by Springer (2010)
ISBN 10: 1441966080 ISBN 13: 9781441966087
Used Hardcover Quantity Available: 1
Print on Demand
Seller:
Ergodebooks
(RICHMOND, TX, U.S.A.)
Rating
[?]

Book Description Springer, 2010. Hardcover. Book Condition: Used: Good. This item is printed on demand. Bookseller Inventory # SONG1441966080

More Information About This Seller | Ask Bookseller a Question

Buy Used
US$ 135.23
Convert Currency

Add to Basket

Shipping: US$ 4.99
Within U.S.A.
Destination, Rates & Speeds

2.

Published by Springer-Verlag New York Inc., United States (2010)
ISBN 10: 1441966080 ISBN 13: 9781441966087
New Hardcover Quantity Available: 1
Seller:
The Book Depository US
(London, United Kingdom)
Rating
[?]

Book Description Springer-Verlag New York Inc., United States, 2010. Hardback. Book Condition: New. 2010 ed.. Language: English . Brand New Book. Angiogenesis (formation of new vessels from pre-existing ones) is a crucial early event in the process of tumor development. New vessels supply the tumor with nutrients that are needed for further local growth and enable distant metastases (Folkman 1995). Judah Folkman (1971) highlighted the potential therapeutic imp- cations of tumor angiogenesis. He hypothesized that if tumor angiogenesis is inhibited, then tumor growth and metastasis will be impaired greatly or even impossible. The subsequent quest for endogenous and exogenous inhibitors of angiogenesis has yielded a variety of promising therapeutic agents that block one or more angiogenic pathways, a few of which have been approved by the FDA (e. g. , bevacizumab, sorafenib, sunitinib) for use as single agents or in combination with chemotherapy in specific populations of cancer patients (Sessa et al. 2008). There has also been a dramatic expansion in the exploration of novel anti-angiogenic agents pre-clinically and in clinical trials (Ferrara 2002). Some of the most promising data comes from the development of agents that inhibit one of the key growth factors involved in tumor angiogenesis - vascular endothelial growth factor (VEGF) (Ferrara et al. 2003). Bevacizumab is a monoclonal antibody against VEGF that was the first an- angiogenic agent that improved significantly the overall survival of patients with colorectal and non-squamous non-small cell lung cancer (Ferrara et al. 2005). Various agents that target tumor angiogenesis are currently under investigation in different cancer types in many clinical trials (Ferrara and Kerbel 2005). Bookseller Inventory # LIB9781441966087

More Information About This Seller | Ask Bookseller a Question

Buy New
US$ 231.41
Convert Currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, Rates & Speeds

3.

Meyer, Tim
ISBN 10: 1441966080 ISBN 13: 9781441966087
New Quantity Available: 1
Seller:
Paperbackshop-US
(Wood Dale, IL, U.S.A.)
Rating
[?]

Book Description 2010. HRD. Book Condition: New. New Book. Shipped from US within 10 to 14 business days. Established seller since 2000. Bookseller Inventory # KS-9781441966087

More Information About This Seller | Ask Bookseller a Question

Buy New
US$ 227.43
Convert Currency

Add to Basket

Shipping: US$ 3.99
Within U.S.A.
Destination, Rates & Speeds

4.

Meyer, Tim
Published by Springer-Verlag New York Inc. (2010)
ISBN 10: 1441966080 ISBN 13: 9781441966087
New Quantity Available: > 20
Print on Demand
Seller:
Books2Anywhere
(Fairford, GLOS, United Kingdom)
Rating
[?]

Book Description Springer-Verlag New York Inc., 2010. HRD. Book Condition: New. New Book. Delivered from our US warehouse in 10 to 14 business days. THIS BOOK IS PRINTED ON DEMAND.Established seller since 2000. Bookseller Inventory # IP-9781441966087

More Information About This Seller | Ask Bookseller a Question

Buy New
US$ 236.34
Convert Currency

Add to Basket

Shipping: US$ 12.16
From United Kingdom to U.S.A.
Destination, Rates & Speeds

5.

Published by Springer-Verlag New York Inc., United States (2010)
ISBN 10: 1441966080 ISBN 13: 9781441966087
New Hardcover Quantity Available: 1
Seller:
The Book Depository
(London, United Kingdom)
Rating
[?]

Book Description Springer-Verlag New York Inc., United States, 2010. Hardback. Book Condition: New. 2010 ed.. Language: English . Brand New Book. Angiogenesis (formation of new vessels from pre-existing ones) is a crucial early event in the process of tumor development. New vessels supply the tumor with nutrients that are needed for further local growth and enable distant metastases (Folkman 1995). Judah Folkman (1971) highlighted the potential therapeutic imp- cations of tumor angiogenesis. He hypothesized that if tumor angiogenesis is inhibited, then tumor growth and metastasis will be impaired greatly or even impossible. The subsequent quest for endogenous and exogenous inhibitors of angiogenesis has yielded a variety of promising therapeutic agents that block one or more angiogenic pathways, a few of which have been approved by the FDA (e. g. , bevacizumab, sorafenib, sunitinib) for use as single agents or in combination with chemotherapy in specific populations of cancer patients (Sessa et al. 2008). There has also been a dramatic expansion in the exploration of novel anti-angiogenic agents pre-clinically and in clinical trials (Ferrara 2002). Some of the most promising data comes from the development of agents that inhibit one of the key growth factors involved in tumor angiogenesis - vascular endothelial growth factor (VEGF) (Ferrara et al. 2003). Bevacizumab is a monoclonal antibody against VEGF that was the first an- angiogenic agent that improved significantly the overall survival of patients with colorectal and non-squamous non-small cell lung cancer (Ferrara et al. 2005). Various agents that target tumor angiogenesis are currently under investigation in different cancer types in many clinical trials (Ferrara and Kerbel 2005). Bookseller Inventory # LIB9781441966087

More Information About This Seller | Ask Bookseller a Question

Buy New
US$ 240.22
Convert Currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, Rates & Speeds

6.

Meyer, Tim
Published by Springer (2016)
ISBN 10: 1441966080 ISBN 13: 9781441966087
New Paperback Quantity Available: 1
Print on Demand
Seller:
Ria Christie Collections
(Uxbridge, United Kingdom)
Rating
[?]

Book Description Springer, 2016. Paperback. Book Condition: New. PRINT ON DEMAND Book; New; Publication Year 2016; Not Signed; Fast Shipping from the UK. No. book. Bookseller Inventory # ria9781441966087_lsuk

More Information About This Seller | Ask Bookseller a Question

Buy New
US$ 245.27
Convert Currency

Add to Basket

Shipping: US$ 5.23
From United Kingdom to U.S.A.
Destination, Rates & Speeds

7.

TIM MEYER
Published by Springer (2010)
ISBN 10: 1441966080 ISBN 13: 9781441966087
New Hardcover Quantity Available: 1
Seller:
Herb Tandree Philosophy Books
(Stroud, GLOS, United Kingdom)
Rating
[?]

Book Description Springer, 2010. Hardback. Book Condition: NEW. 9781441966087 This listing is a new book, a title currently in-print which we order directly and immediately from the publisher. Bookseller Inventory # HTANDREE0298052

More Information About This Seller | Ask Bookseller a Question

Buy New
US$ 260.92
Convert Currency

Add to Basket

Shipping: US$ 10.81
From United Kingdom to U.S.A.
Destination, Rates & Speeds

8.

Meyer
ISBN 10: 1441966080 ISBN 13: 9781441966087
New Hardcover Quantity Available: 1
Seller:
AussieBookSeller
(SILVERWATER, NSW, Australia)
Rating
[?]

Book Description 2010. Hardcover. Book Condition: New. Hardcover. Angiogenesis (formation of new vessels from pre-existing ones) is a crucial early event in the process of tumor development. New vessels supply the tumor with nutrients that a.Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. 256 pages. 0.616. Bookseller Inventory # 9781441966087

More Information About This Seller | Ask Bookseller a Question

Buy New
US$ 271.74
Convert Currency

Add to Basket

Shipping: US$ 37.00
From Australia to U.S.A.
Destination, Rates & Speeds

9.

Tim Meyer (editor)
Published by Springer New York 2010-09-10, New York |London (2010)
ISBN 10: 1441966080 ISBN 13: 9781441966087
New Hardcover Quantity Available: > 20
Seller:
Blackwell's
(Oxford, OX, United Kingdom)
Rating
[?]

Book Description Springer New York 2010-09-10, New York |London, 2010. hardback. Book Condition: New. Bookseller Inventory # 9781441966087

More Information About This Seller | Ask Bookseller a Question

Buy New
US$ 275.44
Convert Currency

Add to Basket

Shipping: US$ 8.10
From United Kingdom to U.S.A.
Destination, Rates & Speeds

10.

Published by Springer
ISBN 10: 1441966080 ISBN 13: 9781441966087
New Hardcover Quantity Available: > 20
Seller:
BuySomeBooks
(Las Vegas, NV, U.S.A.)
Rating
[?]

Book Description Springer. Hardcover. Book Condition: New. Hardcover. 258 pages. Dimensions: 9.2in. x 6.1in. x 0.8in.Angiogenesis (formation of new vessels from pre-existing ones) is a crucial early event in the process of tumor development. New vessels supply the tumor with nutrients that are needed for further local growth and enable distant metastases (Folkman 1995). Judah Folkman (1971) highlighted the potential therapeutic imp- cations of tumor angiogenesis. He hypothesized that if tumor angiogenesis is inhibited, then tumor growth and metastasis will be impaired greatly or even impossible. The subsequent quest for endogenous and exogenous inhibitors of angiogenesis has yielded a variety of promising therapeutic agents that block one or more angiogenic pathways, a few of which have been approved by the FDA (e. g. , bevacizumab, sorafenib, sunitinib) for use as single agents or in combination with chemotherapy in specific populations of cancer patients (Sessa et al. 2008). There has also been a dramatic expansion in the exploration of novel anti-angiogenic agents pre-clinically and in clinical trials (Ferrara 2002). Some of the most promising data comes from the development of agents that inhibit one of the key growth factors involved in tumor angiogenesis vascular endothelial growth factor (VEGF) (Ferrara et al. 2003). Bevacizumab is a monoclonal antibody against VEGF that was the first an- angiogenic agent that improved significantly the overall survival of patients with colorectal and non-squamous non-small cell lung cancer (Ferrara et al. 2005). Various agents that target tumor angiogenesis are currently under investigation in different cancer types in many clinical trials (Ferrara and Kerbel 2005). This item ships from multiple locations. Your book may arrive from Roseburg,OR, La Vergne,TN. Hardcover. Bookseller Inventory # 9781441966087

More Information About This Seller | Ask Bookseller a Question

Buy New
US$ 284.27
Convert Currency

Add to Basket

Shipping: US$ 3.95
Within U.S.A.
Destination, Rates & Speeds

There are 8 more copies of this book

View all search results for this book